Evidation Health was launched yesterday out of a partnership between Stanford Heath Care and GE Ventures, the corporate venture capital arm of General Electric, with $6m in funding.

GE Ventures was also an investor in the series A round, raised in January this year, as were Rock Health Seed Fund and Asset Management Ventures. Evidation will be based at GE Venture’s Menlo Park incubator.

Evidation is looking to use big data to validate products and services in the digital health sector. The rapidly growing sector, which spans healthcare apps to patient monitoring software, offers a range of promising technologies which can positively impact upon patient outcomes.

However, evidence to support marketing claims made by digital health startups remains scarce. Evidation looks to provide the data to substantiate those claims.

Deborah Kilpatrick, CEO at Evidation, said: “We apply expertise in health outcomes research and product commercialisation with behavioural and predictive analytics to help the best management strategies be deployed for the right patients at the right time.

“We envision a digital health-enabled future where clinical interventions can be customised and concentrated in ways that maximise clinical and economic benefit for payers, providers and, most importantly, patients.”

– A version of this article initially appeared on our site, Global University Venturing.

Evidation Health has been launched out of a partnership between Stanford Heath Care and GE Ventures, the corporate venture capital arm of General Electric, with $6m funding.

Backers in Evidation’s venture round include GE Ventures, Rock Health Seed Fund, and Asset Management Ventures, and will be based at GE Venture’s Menlo Park incubator.

The company is looking to use big data to validate products and services in the digital health sector. The rapidly growing sector, which spans healthcare apps to patient monitoring software, offers a range of promising technologies which can positively impact upon patient outcomes. However, evidence to support marketing claims made by digital health startups remains scarce. Evidation looks to provide the data to substantiate those claims.

Deborah Kilpatrick, CEO at Evidation, said: “We apply expertise in health outcomes research and product commercialization with behavioural and predictive analytics to help the best management strategies be deployed for the right patients at the right time. We envision a digital health-enabled future where clinical interventions can be customized and concentrated in ways that maximise clinical and economic benefit for payers, providers and, most importantly, patients.”